NEW YORK, Sept. 20, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Renovacor, Inc. ("Renovacor" or the "Company") (NYSE: RCOR), in connection with the proposed acquisition of the Company by Rocket Pharmaceuticals, Inc. ("Rocket Pharmaceuticals") (NASDAQ: RCKT). Under the terms of the merger agreement, the Company's shareholders will receive 0.1676 shares of Rocket Pharmaceuticals common stock for each Renovacor share owned, representing implied per-share merger consideration of approximately $2.34 based upon Rocket Pharmaceuticals' September 19, 2022 closing price of $13.97.
If you own Renovacor shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website:
https://www.weisslaw.co/news-and-cases/rcor
Or please contact:
Joshua Rubin, Esq.
Weiss Law
305 Broadway, 7th Floor
New York, NY 10007
(212) 682-3025
(888) 593-4771
[email protected]
Weiss Law is investigating whether (i) Renovacor's board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the per-share merger consideration adequately compensates Renovacor's shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at [email protected]
SOURCE Weiss Law
![](https://rt.prnewswire.com/rt.gif?NewsItemId=DC78700&Transmission_Id=202209201425PR_NEWS_USPR_____DC78700&DateId=20220920)
Share this article